January -
- Net sales:
SEK 7.0 million (6.8) -
Operating income:
SEK -4.3 million (-4.0) -
Net income for the period:
SEK -4.3 million (-4.1) -
Earnings per share:
SEK -0.06 (-0.06)
Summary of the quarter
- 3% sales growth.
- The first study on whole blood is published showing that Glycosorb® ABO effectively reduces anti-A/B antibodies without increased haemolysis (destruction of red blood cells).
-
The first blood group incompatible kidney transplant with Glycosorb® ABO in
South Africa is performed. Great Ormond Street Hospital inEngland performs its 18th blood group incompatible paediatric heart transplant using Glycosorb® ABO. All transplants have been performed with successful results.- The company's quality system has been inspected and approved by its Notified Body.
- The company's new Head of Marketing and Head of Sales take up their positions and the recruitment process for a dedicated function in the area of transfusion starts.
CEO comment
"Net sales during the first quarter of the year amounted to
This quarter we have seen clear examples of how our G4G strategy is delivering results. The success in
We will continue to focus on the projects and the areas that have the best opportunities building an even stronger Glycorex."
- Johan Lavén, CEO
For more information, please contact:
Johan Lavén, CEO
Email: johan.laven@glycorex.com
Tel: + 46 (0)73 330 92 16
This information is the kind of information
Brief information about the company
Glycosorb® ABO is one of the company's self-developed proprietary medical devices that is used to facilitate blood group-incompatible transplants. Whilst primarily used to facilitate blood group incompatible kidney transplants, Glycosorb® ABO is also used in blood group incompatible liver-, heart-, lung-, and stem cell transplants. More than 60 scientific papers have been published in reputable medical journals, showing excellent short- and long-term outcomes of blood group incompatible transplants performed with Glycosorb® ABO. Glycosorb® ABO has been used in more than 6,000 transplants in over 25 countries. In addition to
The company has also developed a CE-marked medical device product for the production of universal (low titer) blood products and is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis.
https://news.cision.com/glycorex-transplantation/r/glycorex-transplantation-ab--publ--interim-report-january---march-2023,c3773736
https://mb.cision.com/Main/15286/3773736/2078407.pdf
https://mb.cision.com/Public/15286/3773736/959c1199e045dfb3.pdf
(c) 2023 Cision. All rights reserved., source